Combination Antibiotic Zerbaxa Approved

Sanctioned for complicated abdominal, urinary tract infections

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

MONDAY, Dec. 22, 2014 (HealthDay News) -- The combination antibiotic Zerbaxa (ceftolozane/tazobactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated abdominal infections and complicated urinary tract infections.

The approval for abdominal infections was approved in combination with another drug, metronidazole, the agency said in news release. The approval for urinary tract infection includes infection of the kidney.

Zerbaxa is the fourth antibiotic to be FDA-approved in 2014, following approval of Dalvance (dalbavancin), Sivextro (tedizolid) and Orbactiv (oritavancin).

The drug's label includes a warning about decreased effectiveness among people with kidney impairment, the FDA said. The most common side effects reported during clinical testing included nausea, diarrhea, headache and fever.

Zerbaxa is marketed by Cubist Pharmaceuticals, based in Lexington, Mass.

More information

To learn more, visit the FDA.

--

Last Updated: